CD22 TCR工程T细胞在不引起炎症反应的情况下施加抗白血病细胞毒性
Kilyna A Nguyen1, Zhihui Liu2, John S Davies1,3
1Center for Immuno-Oncology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
Science advances
|April 9, 2025
概括
化学抗原受体 (CAR) -T细胞导致细胞因子释放综合征 (CRS),与T细胞受体 (TCR) -T细胞不同. 比较CD22CAR-T细胞和TCR-T细胞显示,CAR-T细胞诱导炎症,突出了TCRs用于更安全的癌症疗法.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体 (CAR) T细胞对B细胞恶性瘤有效.
- 卡特-T疗法可能会导致炎症性毒性,如细胞因子释放综合征 (CRS).
- 经过T细胞受体 (TCR) 工程的T细胞很少引起CRS.
研究的目的:
- 为了比较针对相同抗原的CAR-T和TCR-T细胞的炎症潜力.
- 在模型系统中研究受体类型如何影响炎症反应.
- 评估CD22 CAR-T和CD22 TCR-T细胞的治疗疗效和安全性.
主要方法:
- 发现了一个CD22特定的TCR.
- 在临床前模型中,CD22 CAR-T细胞和CD22 TCR-T细胞的比较.
- 在异种移植中评估抗白血病活性.
- 分析炎症通路的上调,以应对抗原的参与.
主要成果:
- 无论是CD22 CAR-T细胞还是CD22 TCR-T细胞都在异种移植中消除了白血病.
- 只有CD22 CAR-T细胞诱导了剂量依赖的全身炎症.
- 与TCR-T细胞相比,CAR-T细胞显示出不成比例的炎症途径上调.
- 在抗原接触时,CAR-T细胞没有显示出细胞毒性途径的协同增强.
结论:
- 受体类型 (CAR与TCR) 的差异显著影响炎症反应.
- 卡尔-T细胞比TCR-T细胞引起更大的全身炎症,即使准相同的抗原.
- 由于减少炎症潜力,TCR工程T细胞可能为癌症免疫疗法提供更安全的替代方案.
相关概念视频
Cytotoxic T Cells-mediated Immune Response
740
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
740
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
T Cell Activation and Clonal Selection
550
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
550
T Cell Types and Functions
643
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
643
Tumor Immunotherapy
411
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
411


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)